

# Keryx

[View the current Keryx Page on BioPortfolio.com](http://www.bioportfolio.com/biocorporate/6071-Keryx.html) (<http://www.bioportfolio.com/biocorporate/6071-Keryx.html>)

## Contact Details:

101 Main Street, 17th Floor  
Cambridge  
MA  
02142  
United States of America

Tel: +1 617 494 5515

Fax: +1 617 494 6658

Email: [info@keryx.com](mailto:info@keryx.com)

## Recent Publications by Keryx:



- [The evolving role of aromatase inhibitors in adjuvant breast cancer therapy.](#)  
*The development of third-generation aromatase inhibitors (AIs) has brought...* 13th December, 2005  
Carol Franc Buck Breast Care Center, University of California San- Clin Breast Cancer. 2005 Aug;6(3):206-15.
- [Antidiabetic effect of novel modulating peptides of G-protein-coupled kinase in experimental models of diabetes.](#)  
*AIMS/HYPOTHESIS: G-protein-coupled receptor kinases (GRKs) play a key role...* 8th March, 2005  
Keryx Biopharmaceuticals, Jerusalem, Israel.- Diabetologia. 2004 Jul;47(7):1232-44. Epub 2004 Jul 3. ([DOI Direct Link](#))
- [Sequence-based design of kinase inhibitors applicable for therapeutics and target identification.](#)  
*A platform for specifically modulating kinase-dependent signaling using...* 11th February, 2004  
Keryx Biopharmaceuticals, 15 Yad-Haruzim St., Jerusalem 93420, Israel.- J Biol Chem. 2004 Jan 9;279(2):1242-55. Epub 2003 Oct 21. ([DOI Direct Link](#))
- [Induction of pro-angiogenic signaling by a synthetic peptide derived from the second intracellular loop of S1P3 \(EDG3\).](#)  
*The G-protein-coupled receptors of the endothelial differentiation gene...* 18th October, 2003  
Keryx Biopharmaceuticals, Jerusalem, Israel.- Blood. 2003 Sep 15;102(6):2099-107. Epub 2003 May 22. ([DOI Direct Link](#))

## Press Releases on Keryx:

<a href="#">AEterna Zentaris Partner, Keryx Biopharmaceuticals, Announces Poster Presentation Highlighting Clinical Activity of Perifosine (KRX-0401) at 51st Annual Meeting of the American Society of Hematology</a>	11th November, 2009	AETERNA ZENTARIS INC.	<i>Updated Analyses of Phase 1/2 Clinical Trial of Perifosine in Combination with Bortezomib (+/- Dexamethasone) to be Presented on Saturday, December 5, 2009 QUEBEC CITY, Nov. 11</i>
<a href="#">Keryx Biopharmaceuticals Announces Poster Presentation Highlighting Clinical Activity of KRX-0401 (Perifosine) at the 51st Annual Meeting of the American Society of Hematology</a>	11th November, 2009	Keryx Biopharmaceuticals, Inc.	<i>NEW YORK, Nov. 11 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX) today announced that data from its Phase 1/2 clinical trial of KRX-0401 (perifosine) in combination with</i>
<a href="#">AEterna Zentaris Reports Third Quarter 2009 Financial and Operating Results</a>	11th November, 2009	AETERNA ZENTARIS INC.	<i>All amounts are in U.S. dollars QUEBEC CITY, Nov. 11 /PRNewswire-FirstCall/ - AEterna Zentaris Inc. (NASDAQ: AEZS, TSX: AEZ) (the "Company"), a global biopharmaceutical company focused on</i>
<a href="#">Keryx Biopharmaceuticals, Inc. Announces Third Quarter 2009 Financial Results</a>	9th November, 2009	Keryx Biopharmaceuticals, Inc.	<i>NEW YORK, Nov. 9 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX), a biopharmaceutical company focused on the acquisition, development and commercialization of medically</i>
<a href="#">AEterna Zentaris: Scientific Article Supports Perifosine's Development in Kidney Cancer</a>	9th November, 2009	AETERNA ZENTARIS INC.	<i>Article published in December 2009 issue of the Journal of Urology QUEBEC CITY, Nov. 9 /PRNewswire-FirstCall/ - AEterna Zentaris Inc. (NASDAQ: AEZS; TSX: AEZ) (the "Company"), a global</i>

## BioNews Results for Keryx



- [AEterna Zentaris Partner, Keryx Biopharmaceuticals, Announces Poster Presentation Highlighting](#)

[Clinical Activity of Perifosine \(KRX-0401\) at 51st Annual Meeting of the American Society of Hematology](#)

SmartBrief: Nov 15 2009 4:45AM Matching: keryx

- [Keryx Biopharmaceuticals Announces Poster Presentation Highlighting Clinical Activity of KRX-0401 \(Perifosine\)](#)  
Genetic Engineering News: Nov 12 2009 12:30PM Matching: keryx
- [Aeterna Zentaris Partner, Keryx Biopharmaceuticals, Announces Poster Presentation Highlighting Clinical](#)  
Pharma Live: Nov 12 2009 12:05AM Matching: keryx
- [Keryx Biopharmaceuticals to present KRX-0401 Phase 1/2 clinical trial data at the ASH meeting](#)  
News-Medical.Net: Nov 12 2009 10:53PM Matching: keryx
- [Aeterna Zentaris Partner, Keryx Biopharmaceuticals, Announces Poster Presentation Highlighting Clinical Activi](#)  
Entrepreneur.com: Nov 12 2009 3:49PM Matching: keryx
- [RothmanResearch.com Market Review and Company Analysis on WMT, ARE, ENI, WL, ISRG and KERX](#)  
RBC Dain Rauscher: Nov 12 2009 12:57PM Matching: keryx
- [Keryx Biopharmaceuticals Announces Poster Presentation Highlighting Clinical Activity of KRX-0401 \(Perifosine\)](#)  
Montana's News Station: Nov 11 2009 3:24PM Matching: keryx
- [Keryx Biopharmaceuticals Announces Poster Presentation Highlighting Clinical Activity of KRX-0401 \(Perifosine\) at the 51st Annual Meeting of the Ameri](#)  
Yahoo! Canada: Nov 11 2009 3:11PM Matching: keryx
- [Keryx Biopharmaceuticals Announces Poster Presentation](#)  
PR Newswire via MSN Money: Nov 11 2009 1:44PM Matching: keryx
- [Keryx Biopharmaceuticals Announces Poster Presentation Highlighting Clinical Activity of KRX-0401 \(Perifosine\) at the 51st Annual Meeting of the American Society of Hematology](#)  
Red Orbit: Nov 11 2009 4:32PM Matching: keryx
- [Keryx Biopharmaceuticals Announces Poster Presentation Highlighting Clinical Activity of KRX-0401 \(Perifosine\) at the 51st Annual Meeting of the American Society of Hematology](#)  
Red Orbit: Nov 11 2009 4:30PM Matching: keryx
- [Keryx Biopharmaceuticals Announces Poster Presentation Highlighting Clinical Activity of KRX-0401 \(Perifosine\)](#)  
Yahoo! Canada: Nov 11 2009 1:44PM Matching: keryx
- [Aeterna Zentaris reports consolidated revenues of \\$8.6 million for third quarter 2009](#)  
News-Medical.Net: Nov 11 2009 2:03PM Matching: keryx
- [Aeterna Zentaris Reports Third Quarter 2009 Financial and Operating Results](#)  
Canada NewsWire: Nov 11 2009 12:46PM Matching: keryx
- [Aeterna Zentaris Reports Third Quarter 2009 Financial and Operating Results](#)  
Earthtimes.org: Nov 11 2009 12:15PM Matching: keryx

**Keryx Clinical Trials:**



- [Clinical and Molecular-Metabolic Phase II Trial of Perifosine for Recurrent/Progressive Malignant Gliomas](#)

## BioCorporate Profiles - upgrade to a full profile

BioPortfolio's BioCorporate full profiles offers your organization the opportunity to increase internet traffic to your corporate web site and enhance awareness of your business, technology, products and services. BioCorporate profiles are dynamic and are updated weekly with new information sourced from core information resources: publications, clinical trials, patents and global news.

Why you should upgrade your BioPortfolio BioCorporate profile:

- the ability to amend and add information on products and services to your profile using a membership username and password
- the option to add a corporate logo
- the creation of high value URL links back to your organization's website which will improve search engine ranking - resulting in increased site traffic
- the option have your press releases published on BioPortfolio and distributed via our BioNewsCast service
- an enhanced BioCorporate profile will also improve your exposure on BioPortfolio's related service InDepth and GeneDB

The annual cost is \$995.00 for established organizations and \$495.00 for organizations less than 12 months old.

\*\*\*

Resources from the [NCBI](#) used in this document, [NCBI's standard disclaimer applies](#).

Nothing in this document should be used in place of personal medical advice from your own qualified medical practitioner. See BioPortfolio.com [User Agreement](#)

Send comments and feedback to:

Peter Barfoot Managing Director, BioPortfolio Ltd.

UK Tel: (+44) 1300 321501

USA Voicemail and Fax: (+1) 415 680 2472

[Peter Barfoot peter.barfoot@bioportfolio.com](mailto:peter.barfoot@bioportfolio.com)

All rights reserved. All other trademarks recognized.

BioPortfolio Limited is registered in England & Wales at Stafford House, 10 Prince of Wales Road, Dorchester, Dorset, DT1 1PW, UK. No.3312883 VAT No. GB 744 6483 10

Copyright 1997-2009 - BioPortfolio Limited.

